Charcot-Marie-Tooth disease

  • CLN-PXT3003-06_PREMIER: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)

 

Acronym

CLN-PXT3003-06_PREMIER

Intervention PXT3003
Principal investigator Giorgia Querin
Sponsor Pharnext
Study status In preparation
Recruitment status In preparation
Population Adult
   + infos on clinical trials.gov